Chris Parsons - Search Results

Year	Number of Results
1990	1
2001	1
2002	2
2003	2
2004	2
2005	3
2006	5
2007	3
2008	3
2009	3
2010	8
2011	11
2012	13
2013	13
2014	9
2015	6
2016	3
2017	5
2018	3
2019	2
2020	4
2021	2
2022	6
2023	6
2024	2

1

Memantine: Updating a rare success story in pro-cognitive therapeutics.

Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Karimi Tari P, et al. Among authors: parsons cg. Neuropharmacology. 2024 Feb 15;244:109737. doi: 10.1016/j.neuropharm.2023.109737. Epub 2023 Oct 11. Neuropharmacology. 2024. PMID: 37832633 Free article. Review.

2

Standard Candles for Dating Microbial Lineages.

Fournier GP, Parsons CW, Cutts EM, Tamre E. Fournier GP, et al. Among authors: parsons cw. Methods Mol Biol. 2022;2569:41-74. doi: 10.1007/978-1-0716-2691-7_3. Methods Mol Biol. 2022. PMID: 36083443

3

Emmprin and KSHV: new partners in viral cancer pathogenesis.

Dai L, Bai L, Lu Y, Xu Z, Reiss K, Del Valle L, Kaleeba J, Toole BP, Parsons C, Qin Z. Dai L, et al. Among authors: parsons c. Cancer Lett. 2013 Sep 1;337(2):161-6. doi: 10.1016/j.canlet.2013.05.037. Epub 2013 Jun 3. Cancer Lett. 2013. PMID: 23743354 Free PMC article. Review.

4

CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance.

Grass GD, Dai L, Qin Z, Parsons C, Toole BP. Grass GD, et al. Among authors: parsons c. Adv Cancer Res. 2014;123:351-73. doi: 10.1016/B978-0-12-800092-2.00013-7. Adv Cancer Res. 2014. PMID: 25081536 Review.

5

Preclinical to phase II amyloid beta (A_β) peptide modulators under investigation for Alzheimer's disease.

Parsons CG, Rammes G. Parsons CG, et al. Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832. Expert Opin Investig Drugs. 2017. PMID: 28362514 Review.

6

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.

Francis PT, Parsons CG, Jones RW. Francis PT, et al. Among authors: parsons cg. Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124. Expert Rev Neurother. 2012. PMID: 23234396 Review.

7

Possible levetiracetam-induced aseptic meningitis versus viral meningitis: Case report and literature review.

Vickery SB, Roach JK, Parsons C, Vickery PB. Vickery SB, et al. Among authors: parsons c. Nurse Pract. 2022 Jul 1;47(7):32-37. doi: 10.1097/01.NPR.0000843216.79693.7e. Nurse Pract. 2022. PMID: 35758918 Review. No abstract available.

8

CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity.

Parsons CG. Parsons CG. Neuropharmacology. 2019 Mar 15;147:4-10. doi: 10.1016/j.neuropharm.2018.08.027. Epub 2018 Aug 27. Neuropharmacology. 2019. PMID: 30165077 Review.

9

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Parsons CG, Danysz W, Dekundy A, Pulte I. Parsons CG, et al. Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9. Neurotox Res. 2013. PMID: 23657927 Free PMC article. Review.

10

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Danysz W, Parsons CG. Danysz W, et al. Among authors: parsons cg. Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x. Br J Pharmacol. 2012. PMID: 22646481 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year